Expertise in
2
conditions

Silvy Lachance

Montreal, QC, CA 
Expertise in
2
conditions
Montreal, QC, CA 

Overview

Silvy Lachance practices practicing medicine in Montreal, Canada.

Lachance is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Leukemia, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 3 clinical trials.

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Ridgetown, ON, Canada
Alfred, ON K0B1A0, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation
Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation
Enrollment Status: Withdrawn
Publish Date: October 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor
Enrollment Status: Completed
Publish Date: August 05, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

34 Total Publications

Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy.
Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy.
Journal: Bone marrow transplantation
Published: January 21, 2026

Frequently Asked Questions about Silvy Lachance

Is Silvy Lachance a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Silvy Lachance is classified as an Distinguished expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Silvy Lachance participate in research or clinical trials?

Yes. Silvy Lachance has published 34 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Silvy Lachance's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lachance's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile